ArticleGenes, chromosomes & cancer2009
Protocadherin PCDH10, involved in tumor progression, is a frequent and early target of promoter hypermethylation in cervical cancer.
Article in Genes, chromosomes & cancer, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 94 citations in OpenAlex.
- Do Protocadherins Show Prognostic Value in the Carcinogenesis of Human Malignant Neoplasms? Systematic Review and Meta-Analysis.Asian Pacific journal of cancer prevention : APJCP · 2020Pooled it
- Classic Protocadherin PCDH10 Functions as a Tumor Suppressive Scaffold Protein Antagonizing Oncogenic WNT/β-catenin Signaling in Breast Carcinogenesis.International journal of biological sciences · 2026Article
- Modeling the lymph node stromal cells in oral squamous cell carcinoma: insights into the stromal cues in nodal metastasis.Human cell · 2025Article
- The role of Pcdh10 in neurological disease and cancer.Journal of cancer research and clinical oncology · 2023Review
- The pan-cancer landscape of abnormal DNA methylation and intratumor microorganisms.Neoplasia (New York, N.Y.) · 2023Article
- Innovative mouse models for the tumor suppressor activity of Protocadherin-10 isoforms.BMC cancer · 2022Article
- Review
- Protocadherins at the Crossroad of Signaling Pathways.Frontiers in molecular neuroscience · 2020Review
- High methylation levels of PCDH10 predict poor prognosis in patients with pancreatic ductal adenocarcinoma.BMC cancer · 2019Article
- Cadherin Related Family Member 2 Acts As A Tumor Suppressor By Inactivating AKT In Human Hepatocellular Carcinoma.Journal of Cancer · 2019Article
- PCDH20 acts as a tumour-suppressor gene through the Wnt/β-catenin signalling pathway in hypopharyngeal squamous cell carcinoma.Cancer biomarkers : section A of Disease markers · 2019Article
- Protocadherin 17 is a tumor suppressor and is frequently methylated in nasopharyngeal carcinoma.Cancer management and research · 2019Article
- The role of lncRNAs in the development of endometrial carcinoma.Oncology letters · 2018Review
- Expression of protocadherin8: Function as a tumor suppressor in hypopharyngeal carcinoma.Cancer biomarkers : section A of Disease markers · 2018Article
- Regulation of Wnt signaling by protocadherins.Seminars in cell & developmental biology · 2017Review
- Dysregulated expression of long noncoding RNAs in gynecologic cancers.Molecular cancer · 2017Review
- Epigenetic silencing of protocadherin 10 in colorectal cancer.Oncology letters · 2017Article
- Aberrant expression and functions of protocadherins in human malignant tumors.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Review
- CXCL12 is a key regulator in tumor microenvironment of cervical cancer: an in vitro study.Clinical & experimental metastasis · 2016Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 4 countries.
Funding
Abstract
Cervical cancer (CC) is the second most common cancer in women. Currently, no tractable molecular-based therapeutic targets exist for patients with invasive CC and no predictive markers of risk assessment for progression of precancerous lesions are identified. New molecular insights into CC pathogenesis are urgently needed. Towards this goal, we first determined the copy number alterations of chromosome 4 and then examined the role of PCDH10 mapped to 4q28 as a candidate tumor suppressor gene. We identified monosomy 4 in 47% of 81 invasive CC studied by SNP array and found that 91% of 130 invasive CC harboring methylation in the promoter region of the PCDH10 gene. We then showed that aberrant promoter hypermethylation of PCDH10 is associated with downregulation of gene expression and cell lines exposed to demethylating agent resulted in profound reactivated gene expression. We also showed that the promoter methylation in the PCDH10 gene occurs at an earliest identifiable stage of low-grade squamous intraepithelial lesion. Our studies demonstrate that inactivation of PCDH10 may be a critical event in CC progression and form a potentially useful therapeutic target for CC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.